FDA OKs expanded use of iron deficiency drug: 3 things to know

AMAG Pharmaceuticals on Monday earned expanded FDA approval for its chronic kidney disease treatment Feraheme.

Advertisement

Here are three things to know.

1. The FDA first approved Feraheme in 2009 to treat iron deficiency anemia in adults with chronic kidney disease.

2. The drug may now also be used to treat all adults with IDA who do not respond to or are intolerant to oral iron.

3. The expanded approval doubles the amount of patients who may benefit from the drug, which is administered as an injection.

More articles on supply chain:

Pfizer’s opioid-filled syringes hit another manufacturing snag: 6 things to know
Amazon patents wristband that monitors supply workers’ hand movements
4 latest FDA approvals

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.